Clinical Trial Results:
Two treatment strategies with Ribavirin for Chronic Hepatitis E and severe acute forms randomized study
Summary
|
|
EudraCT number |
2015-000699-91 |
Trial protocol |
ES |
Global end of trial date |
07 Nov 2018
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
30 Jan 2022
|
First version publication date |
30 Jan 2022
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
RACHE
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
VHIR
|
||
Sponsor organisation address |
Passeig Vall Hebron 119-129, Barcelona, Spain, 08035
|
||
Public contact |
Joaquin Lopez-Soriano, Fundación Hospital Vall Hebron Institut de Recerca, 0034 934894779, joaquin.lopez.soriano@vhir.org
|
||
Scientific contact |
Servicio Hepatología, Fundación Hospital Vall Hebron Institut de Recerca, 0034 934893000, resteban@vhebron.net
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
07 Nov 2018
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
07 Nov 2018
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
Efficacy assessment (sustained virologic response rate) with Ribavirin in two therapeutic strategies with ribavirin, in patients with chronic and severe acute hepatitis E.
|
||
Protection of trial subjects |
No specific measures were necessary
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Sep 2015
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Spain: 5
|
||
Worldwide total number of subjects |
5
|
||
EEA total number of subjects |
5
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
4
|
||
From 65 to 84 years |
1
|
||
85 years and over |
0
|
|
||||||||||
Recruitment
|
||||||||||
Recruitment details |
Patients were recruited at Vall Hebron Hospital (Barcelona, Spain) | |||||||||
Pre-assignment
|
||||||||||
Screening details |
Patients were selected form the CHES (Chronic Hepatitis E Screening) multicenter study including patients with immune impairment and increased transaminases levels. 381 patients in total were included in that study, from which patients were selected. | |||||||||
Period 1
|
||||||||||
Period 1 title |
Overall trial (overall period)
|
|||||||||
Is this the baseline period? |
Yes | |||||||||
Allocation method |
Randomised - controlled
|
|||||||||
Blinding used |
Not blinded | |||||||||
Arms
|
||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||
Arm title
|
12 weeks | |||||||||
Arm description |
12 weeks treatment with ribavarin | |||||||||
Arm type |
Experimental | |||||||||
Investigational medicinal product name |
Ribavirin
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||
Routes of administration |
Oral use
|
|||||||||
Dosage and administration details |
600mg daily dose for 12 weeks
|
|||||||||
Arm title
|
24 weeks | |||||||||
Arm description |
24 weeks treatment if RNA detectable at 4 weeks after starting treatment, or else treatment only 12 weeks if RNA undetectable at 4 weeks | |||||||||
Arm type |
Experimental | |||||||||
Investigational medicinal product name |
Ribavirin
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||
Routes of administration |
Oral use
|
|||||||||
Dosage and administration details |
600mg daily dose for: 12 weeks if RNA not detectable at week 4; or 24 weeks if RNA detectable at 4 weeks, adjusted to renal function
|
|||||||||
|
|
||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||
Reporting group title |
Overall trial
|
|||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
12 weeks
|
||
Reporting group description |
12 weeks treatment with ribavarin | ||
Reporting group title |
24 weeks
|
||
Reporting group description |
24 weeks treatment if RNA detectable at 4 weeks after starting treatment, or else treatment only 12 weeks if RNA undetectable at 4 weeks |
|
|||||||||||||
End point title |
RNA not detectable [1] | ||||||||||||
End point description |
Hepatatis E Virus RNA levels were assessed 48 weeks after ending of treatment
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
48 weeks after finishing treatment
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The small sample size makes impossible a statistical analysis |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
48 weeks after tretament
|
||
Assessment type |
Systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
MedDRA | ||
Dictionary version |
22.1
|
||
Frequency threshold for reporting non-serious adverse events: 5% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: None adverse events were reported in the study |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
Small sample size makes desirable further studies with larger groups |